Literature DB >> 22732652

EP4 receptors mediate prostaglandin E2, tumour necrosis factor alpha and interleukin 1beta-induced ion secretion in human and mouse colon mucosa.

Sian E Fairbrother1, Julia E Smith, Richard A Borman, Helen M Cox.   

Abstract

Prostaglandin E(2) (PGE(2)) is an inflammatory mediator implicated in several gastrointestinal pathologies that cause diarrhoea. The aim of this study was to establish the contributions of the four different EP receptors (EP(1-4)) to PGE(2)-induced anion secretion in human and mouse colon mucosa. Electrogenic anion secretion (short-circuit current; I(sc)) was measured across colonic mucosae or T84 monolayers placed in Ussing chambers in response to EP receptor agonists and antagonists. PGE(2) and PGE(1)-alcohol increased I(sc) in human colon mucosa, T84 epithelia and mouse colon mucosa, and these responses were inhibited by the EP(4) receptor antagonist, GW627368X alone. In addition, the EP(2) agonist, butaprost increased I(sc) in all three preparations and these responses were inhibited by the non-selective EP(1,2,3) receptor antagonist, AH6809 but not by GW627368X. Conversely, responses mediated by EP(1) and EP(3) receptors were not observed in human colon or T84 monolayers. However, in mouse colon mucosa the EP(3)-preferring agonist, sulprostone reduced I(sc), indicative of G(iα)-signalling. Taken together these results indicate that PGE(2)-induced ion secretion is mediated predominantly by G(s)-coupled EP(4) receptors and also by EP(2) receptors in human mucosa. Furthermore, tumour necrosis factor alpha (TNFα) and interleukin 1beta (IL1β) increased I(sc) and these responses were also inhibited by the EP(4) receptor antagonist in human colon mucosa. This study establishes the EP receptor pharmacology present in human epithelial preparations, and suggests that EP(4) receptors may be a therapeutic target for the treatment of secretory diarrhoea where PGE(2) is implicated in the aetiology.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22732652     DOI: 10.1016/j.ejphar.2012.06.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.

Authors:  Sheetal Parida; Aditya Parekh; Goutam Dey; Sukhen C Ghosh; Mahitosh Mandal
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  Nanomolar EP4 receptor potency and expression of eicosanoid-related enzymes in normal appearing colonic mucosa from patients with colorectal neoplasia.

Authors:  Ulrike Ries Feddersen; Sebastian Kjærgaard Hendel; Mark Alexander Berner-Hansen; Thomas Andrew Jepps; Mark Berner-Hansen; Niels Bindslev
Journal:  BMC Gastroenterol       Date:  2022-05-12       Impact factor: 2.847

3.  Mechanisms of antidiarrhoeal effects by diosmectite in human intestinal cells.

Authors:  Vittoria Buccigrossi; Carla Russo; Amedeo Guarino; Maiara Brusco de Freitas; Alfredo Guarino
Journal:  Gut Pathog       Date:  2017-04-24       Impact factor: 4.181

Review 4.  Arachidonic Acid in Human Milk.

Authors:  Norman Salem; Peter Van Dael
Journal:  Nutrients       Date:  2020-02-27       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.